InteRNA Technologies is a clinical-stage biotech company developing a pipeline of proprietary RNA therapeutics targeting key processes in initiation and progression of human diseases, with a focus on cancer. Selected through its leading miRNA discovery and functional validation technology platform and enabled with a 3rd-generation drug delivery formulation, these miRNA compounds can mount a coordinated anti-cancer attack by engaging with multiple signal transduction targets simultaneously. With this approach, we address the high unmet medical need for novel therapeutics with improved efficacy and less prone to drug-acquired resistance that will benefit cancer patients.

InteRNA aspires to improve therapy effectiveness through innovative, intelligent miRNA-based therapeutics for the benefit of patients suffering from cancer and beyond.